SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss reported BOT+BAL data in recurrent ovarian cancer is drawing attention, with traders highlighting an estimated 48% three-year survival rate and durable results. The response is largely upbeat, though some note the small Phase 1b cohort, investigational status, and share-price volatility around the update.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ais quarterly results are driving attention: it reported revenue roughly in line with expectations and a narrower adjusted loss, but revenue remained sharply lower year over year and its next-quarter revenue outlook missed expectations. Traders are split between seeing positive cash flow and stronger bookings as signs of a turnaround and worrying that declining sales and continued losses undermine the recovery case.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

Attention centers on Bankrs AI-agent and onchain trading infrastructure, with traders highlighting Robinhood Chain and BNB integrations, protocol activity, and a reported fee-funded buyback mechanism. Bullish holders see growing utility and potential value accrual, while others are wary of volatile price action and hype.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Traders are positioning for a potential COMP breakout, citing its capped supply and Compounds institutional-market push and planned V4 as reasons for optimism. The bullish accumulation narrative is tempered by complaints that COMP has lagged other crypto assets and by skepticism about whether the developments will translate into stronger price action.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is drawing attention for its payment and tokenization plans, including the ASK Group UAE venture and Keeta Personals fiat and banking features. Bulls see these partnerships as potential drivers of adoption, while skeptics point to weak price action and limited demonstrated network usage.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

WLDs rebound and breakout chatter is being tied by traders to Eightco/ORBSs reported large WLD holdings, with speculation about a Grayscale ETF filing and Worlds proof-of-human role in an AI-driven internet adding to the buzz. Sentiment is broadly bullish but tempered by concerns about sharp volatility and whether the rally can hold.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives finance and RWA expansion, ETF filings, and a proposed tokenomics change that could increase fee-funded burns are driving bullish discussion, with supporters arguing these factors make INJ undervalued. The deflationary shift remains conditional on the proposal, and skeptics point to the tokens prolonged decline and question whether adoption will translate into lasting demand.

PolySwarm

Unusually heavy tradingtraders say South Korean venues account for most of the volumeis driving speculation about another sharp move in PolySwarms NCT token, though they cite no confirmed new catalyst. The discussion is split between bullish hopes for a repeat of past rallies and concerns that the spikes are pump-and-dump activity amid broader crypto-market uncertainty.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAXs sharp rally and elevated volume are being linked by traders to institutional adoption and real-world-asset tokenization, including discussion of a Goldman Sachs fund using an Avalanche-based network and NYSE tokenized-securities testing. The community is divided between seeing these developments as support for further momentum and viewing the move as speculative, with some locking in profits or warning of a pullback.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMs rally toward recent highs is drawing attention amid bullish options activity and reports that it is considering a Texas fab campus, against a broader AI-chip demand narrative. Many traders see continued momentum, while others flag a possible technical pullback and note that the Texas expansion remains under consideration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GPCR is drawing attention after a steep decline despite clinical updates on its oral obesity pipeline, with traders questioning alenigliprons efficacy durability and tolerability, the long Phase 3 timeline, and the prospect of further funding amid weakness across obesity biotechs. Bulls call the valuation attractive given the companys cash and pipeline and speculate about a pharma deal, while bears see a crowded market and unresolved clinical risks.

Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?

NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.

Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

Equity

Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.

Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?

Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.

NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To ‘Novo’ Amid Another Gloomy Year 

NVO has fallen about 12% in 2026 after losing more than half its value in 2025, its worst year since 1984.

Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data

Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.read more...

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

Current Price	$27.67
Prev Close	$28.98
Open	$28.99
Dividend Yield	0.00%
50-Day Moving Average	$44.71
Beta	0.91
Avg. Volume	1.39M
PE Ratio	-8.98

52-Week High	$94.90
52-Week Low	$25.59
Market Capitalization	$1.97B
EPS (Annual)	-$2.39
Price to Book	1.45
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GPCR Fundamentals